Edition:
India

Strongbridge Biopharma plc (SBBP.OQ)

SBBP.OQ on NASDAQ Stock Exchange Global Select Market

6.20USD
22 Jun 2018
Change (% chg)

$-0.10 (-1.59%)
Prev Close
$6.30
Open
$6.35
Day's High
$6.45
Day's Low
$6.15
Volume
2,380,891
Avg. Vol
76,873
52-wk High
$9.25
52-wk Low
$4.75

Chart for

About

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of... (more)

Overall

Beta: --
Market Cap(Mil.): $244.85
Shares Outstanding(Mil.): 39.81
Dividend: --
Yield (%): --

Financials

  SBBP.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -2.76 -- --
ROI: -101.99 14.84 14.38
ROE: -214.59 16.34 16.08

BRIEF-Strongbridge To Host Conference Call On March 12 To Announce Fourth Quarter And Year-End 2017 Results

* STRONGBRIDGE BIOPHARMA PLC TO HOST CONFERENCE CALL ON MARCH 12, 2018 TO ANNOUNCE FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

28 Feb 2018

BRIEF-Strongbridge Biopharma Announces Pricing Of Public Offering

* STRONGBRIDGE BIOPHARMA PLC ANNOUNCES PRICING OF PUBLIC OFFERING OF ORDINARY SHARES

26 Jan 2018

BRIEF-Strongbridge Biopharma Announces Proposed Public Offering Of 5 Mln Ordinary Shares

* STRONGBRIDGE BIOPHARMA PLC ANNOUNCES PROPOSED PUBLIC OFFERING OF 5 MILLION ORDINARY SHARES Source text for Eikon: Further company coverage:

24 Jan 2018

BRIEF-Strongbridge Biopharma Receives Notice Of Allowance From U.S. Patent And Trademark Office For New Patent Covering RECORLEV

* STRONGBRIDGE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FROM U.S. PATENT AND TRADEMARK OFFICE FOR NEW PATENT COVERING RECORLEV™ (LEVOKETOCONAZOLE) FOR THE TREATMENT OF CUSHING’S SYNDROME

18 Jan 2018

BRIEF-Strongbridge Announces Acquisition Of U.S., Canadian Rights To Macrilen From Aeterna Zentaris

* STRONGBRIDGE BIOPHARMA PLC ANNOUNCES ACQUISITION OF THE U.S. AND CANADIAN RIGHTS TO MACRILEN™ (MACIMORELIN) FROM AETERNA ZENTARIS

17 Jan 2018

BRIEF-Aeterna Zentaris Enters Licensing Agreement With Strongbridge For Macrilen In U.S., Canada

* AETERNA ZENTARIS ENTERS INTO LICENSING AND ASSIGNMENT AGREEMENT WITH STRONGBRIDGE FOR MACRILEN™ (MACIMORELIN) IN THE U.S. AND CANADA

17 Jan 2018

Earnings vs. Estimates